VIA Pharmaceuticals Report issue

For profit Phase 2
Founded: San Francisco CA United States (2004)
Status: Defunct (2010)

Organization Overview

First Clinical Trial
2006
NCT00352417
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

Key: VIA Pharmaceuticals (1) Acquired (1)

atreleuton (3 trials)

pvgi.1 (vegf-2) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 2)

Atherosclerosis (Phase 2)

Coronary Artery Disease (Phase 2)

Inflammation (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2